1-1 of 1
Michael J. Yellin
Close
Sort by
Journal Articles

Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies

Stephen M. Ansell, Ian Flinn, Matthew H. Taylor, Branimir I. Sikic, Joshua Brody, John Nemunaitis, Andrew Feldman, Thomas R. Hawthorne, Tracey Rawls, Tibor Keler, Michael J. Yellin
Journal: Blood Advances
Blood Adv (2020) 4 (9): 1917–1926.
https://doi.org/10.1182/bloodadvances.2019001079
Published: 2020
Includes: Supplemental data